MASSARO GEORGE
Known title: DirectorCIK: 0001221496
Associated companies
Transaction History
| CRL | ▼ Sell | Open Market | 35 | $5K | 5/15/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 81 | $11K | 5/15/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 24 | $3K | 5/15/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 91 | $13K | 5/14/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 21 | $3K | 5/14/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 14 | $2K | 5/14/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 7 | $1K | 5/14/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 7 | $1K | 5/14/2025 | View on chart |
| CRL | ▼ Sell | Open Market | 123 | $29K | 5/15/2024 | View on chart |
| CRL | ▼ Sell | Open Market | 113 | $27K | 5/15/2024 | View on chart |
| CRL | ▼ Sell | Open Market | 96 | $23K | 5/15/2024 | View on chart |
| CRL | ▲ Buy | Grant | 559 | $128K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 664 | $0 | 5/15/2023 | View on chart |
| CRL | ▼ Sell | Open Market | 288 | $56K | 5/11/2023 | View on chart |
| CRL | ▲ Buy | Grant | 575 | $0 | 5/11/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 88 | $20K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 24 | $5K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 15 | $3K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 15 | $3K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 13 | $3K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 15 | $4K | 5/9/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 8 | $2K | 5/9/2022 | View on chart |
| CRL | ▲ Buy | Option Exercise | 2,539 | $417K | 8/31/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 1,556 | $688K | 8/31/2021 | View on chart |
| CRL | ▼ Sell | Open Market | 983 | $435K | 8/31/2021 | View on chart |
| CRL | ▼ Sell | Gift | 500 | $0 | 8/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.